Loading
The 2016 revision that cut the six triple-negative subtypes to four after showing the immune and stem-like signals came from surrounding cells, and found that response to standard chemotherapy before surgery ranged from 41 percent in basal-like 1 to 18 percent in basal-like 2.
Lehmann, Jovanović, Chen, Estrada and colleagues used histopathological quantification and laser-capture microdissection to show that transcripts of the immunomodulatory and mesenchymal stem-like subtypes came from infiltrating lymphocytes and tumour-associated stromal cells, and refined the classification to four tumour-specific subtypes (TNBCtype-4: BL1, BL2, M and LAR) that differ in age at diagnosis, grade, local and distant progression and histopathology. Retrospective evaluation of more than 300 triple-negative patients across five public neoadjuvant chemotherapy data sets showed pathological complete response in 41 percent of BL1 (95 percent confidence interval 33 to 51), 18 percent of BL2 (9 to 28) and 29 percent of LAR (17 to 41) tumours.
The first evidence that molecular subtype predicts chemotherapy response in triple-negative disease, and the origin of the observation that the immune signal in these tumours is real and measurable, which tumour-infiltrating lymphocyte scoring later turned into a prognostic tool.
Shares Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, Androgen receptor, Tumour heterogeneity and clonal evolution, RNA sequencing & expression profiling and the tag tnbc-evidence.
Shares Tumour-infiltrating lymphocytes (TILs), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares RNA sequencing & expression profiling, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.